UNSPSC 51373477: Hydrocodone/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373477 Hydrocodone/pseudoephedrine, a Commodity code, describes pharmaceutical products state and local governments procure for healthcare delivery to incarcerated individuals and community health programs. The work being solicited under this code spans parenteral (intravenous) solutions including controlled substances for correctional health plans, as well as opioid-antagonist medications and drug deactivation systems for public health initiatives. State and local issuing bodies soliciting under the code include state departments of corrections and county health or public safety agencies. The Washington State Department of Corrections and Seminole County, Florida have both posted recent opportunities in this space, indicating that the code captures both institutional healthcare supply chains within corrections systems and community-level harm-reduction procurement.

Recent activity shows geographic spread across Washington and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with response deadline October 7, 2026 at 4:00 PM PST, soliciting parenteral nutrition solutions, intravenous solutions, and controlled-substance parenteral products for eight correctional facilities across three regions (West, Central, and East), with anticipation of awarding up to three contractors per region and contract term running November 26, 2026 through June 30, 2030. The RFQ incorporates state set-aside goals for small business (25%), minority-owned business (10%), women-owned business (6%), and veteran-owned business (5%) participation. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023, with potential FEMA funding and two-year initial term plus one-year renewal option.